MA43918A - Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31 - Google Patents

Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31

Info

Publication number
MA43918A
MA43918A MA043918A MA43918A MA43918A MA 43918 A MA43918 A MA 43918A MA 043918 A MA043918 A MA 043918A MA 43918 A MA43918 A MA 43918A MA 43918 A MA43918 A MA 43918A
Authority
MA
Morocco
Prior art keywords
antagonist
prevention
treatment
pharmaceutical composition
active substance
Prior art date
Application number
MA043918A
Other languages
English (en)
French (fr)
Inventor
Yoshinobu Higuchi
Keiko Hirokawa
Yuki Iwayanagi
Akihisa Kaneko
Hidetomo Kitamura
Hiroaki Matsushita
Ryosuke Mihara
Tomohisa Saito
Yumi Yamamoto
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MA43918A publication Critical patent/MA43918A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
MA043918A 2015-04-14 2016-04-13 Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31 MA43918A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015082699 2015-04-14
JP2016041641 2016-03-04

Publications (1)

Publication Number Publication Date
MA43918A true MA43918A (fr) 2018-12-05

Family

ID=57126544

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043918A MA43918A (fr) 2015-04-14 2016-04-13 Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31

Country Status (25)

Country Link
US (3) US10544227B2 (enExample)
EP (2) EP3284480B1 (enExample)
JP (7) JP5954916B1 (enExample)
KR (4) KR102641898B1 (enExample)
CN (2) CN107614016B (enExample)
AU (2) AU2016248786B2 (enExample)
BR (1) BR112017022101A2 (enExample)
CA (1) CA2980992C (enExample)
DK (1) DK3284480T3 (enExample)
ES (1) ES3036076T3 (enExample)
FI (2) FI3284480T3 (enExample)
FR (1) FR25C1042I1 (enExample)
HR (1) HRP20250972T1 (enExample)
HU (2) HUE072989T2 (enExample)
LT (2) LT3284480T (enExample)
MA (1) MA43918A (enExample)
MX (2) MX390570B (enExample)
NL (1) NL301347I2 (enExample)
NO (1) NO2025047I1 (enExample)
PL (1) PL3284480T3 (enExample)
PT (1) PT3284480T (enExample)
RU (1) RU2749512C2 (enExample)
SI (1) SI3284480T1 (enExample)
TW (4) TWI738648B (enExample)
WO (1) WO2016167263A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA43918A (fr) * 2015-04-14 2018-12-05 Chugai Pharmaceutical Co Ltd Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
WO2017126488A1 (ja) * 2016-01-18 2017-07-27 持田製薬株式会社 乾癬治療用組成物および治療方法
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
PT3749353T (pt) * 2018-02-09 2025-10-14 Chugai Pharmaceutical Co Ltd Nemolizumab no tratamento da dermatite atópica com escoriação moderada a grave
US20210054085A1 (en) * 2018-04-25 2021-02-25 Kiniksa Pharmaceuticals, Ltd. Treatment of skin diseases or disorders by delivery of anti-osmrb antibody
CN112512480B (zh) 2018-05-21 2024-10-01 中外制药株式会社 被封入玻璃容器的冷冻干燥制剂
AU2020205073A1 (en) * 2019-01-03 2021-08-19 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
EP4021499A4 (en) * 2019-08-29 2024-08-07 Elanco US Inc. ANTI-IL31 ANTIBODIES FOR VETERINARY USE
CN110563844A (zh) * 2019-09-04 2019-12-13 华中农业大学 一种抗犬白介素31受体的多克隆抗体及其应用
EP4062933A4 (en) 2019-11-20 2023-12-13 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
WO2021151059A1 (en) * 2020-01-24 2021-07-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Compounds and methods for treating or reducing pruritus
WO2022113316A1 (ja) * 2020-11-30 2022-06-02 マルホ株式会社 線維化の進行抑制剤
TW202304510A (zh) * 2021-04-07 2023-02-01 瑞士商葛德瑪控股公司 結節性癢疹之治療
CN115181183B (zh) * 2022-06-23 2023-11-03 恺佧生物科技(上海)有限公司 一种il-31ra抗体以及其构建方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH575014A5 (enExample) 1973-05-25 1976-04-30 Alusuisse
JPS5328498Y2 (enExample) 1973-08-17 1978-07-18
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
BR9204244A (pt) 1992-10-26 1994-05-03 Cofap Ferro fundido cinzento
KR100371784B1 (ko) 1992-12-01 2003-07-22 프로테인 디자인랩스, 인코포레이티드 L-셀렉틴과반응성인인체화된항체
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
FR2729855A1 (fr) 1995-01-26 1996-08-02 Oreal Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
WO1997010354A1 (fr) 1995-09-11 1997-03-20 Kyowa Hakko Kogyo Co., Ltd. Anticorps de la chaine alpha du recepteur de l'interleukine 5 humaine
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
CN1241944A (zh) 1996-12-05 2000-01-19 乔治敦大学 具有抗病毒活性的鼠尾草种类的提取物
JPH11101542A (ja) 1997-09-29 1999-04-13 Sanyo Electric Co Ltd 冷蔵庫
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
NZ507782A (en) 1998-04-30 2003-12-19 Tanox Inc G-CSF receptor agonist antibodies and screening method therefor
FR2780062B1 (fr) 1998-06-17 2000-07-28 Rhone Poulenc Rorer Sa Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
EP1088831A4 (en) 1998-06-24 2003-01-02 Chugai Pharmaceutical Co Ltd HEMOPOIETIN RECEPTOR PROTEINS
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP2325316B8 (en) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, NR10
DE60025241T2 (de) 1999-09-27 2007-01-11 Chugai Seiyaku K.K. HäMOPOIETINREZEPTOR-PROTEIN, NR12
CN1326880A (zh) 2000-06-06 2001-12-19 周伟中 双层站台火车站
US20030096339A1 (en) 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
DK1325115T3 (en) 2000-06-26 2016-11-21 Zymogenetics Inc CYTOKINRECEPTOR ZCYTOR17
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
JP2004526419A (ja) 2000-10-16 2004-09-02 フィロス インク． 抗体模倣物および他の結合タンパク質のためのタンパク質骨格
WO2002077230A1 (fr) 2001-03-26 2002-10-03 Chugai Seiyaku Kabushiki Kaisha Variants d'epissage nr10
EP1754719A3 (en) 2001-04-05 2007-05-16 Immuno-Biological Laboratories Co., Ltd. Anti-osteopontin antibody and use thereof
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
ATE401390T1 (de) 2002-01-18 2008-08-15 Zymogenetics Inc Zytokin (zcytor17-ligand)
EP1576112B1 (en) 2002-01-18 2012-02-29 ZymoGenetics, Inc. Cytokine receptor zcytor17 multimers
EP2110434A1 (en) 2002-02-25 2009-10-21 Genentech, Inc. Type-1 cytokine receptor GLM-R
KR101080587B1 (ko) 2002-05-01 2011-11-04 바이엘 파마 악티엔게젤샤프트 항응고제로서의 신규 조직 인자 표적화된 항체
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
TW200407335A (en) 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
KR100499989B1 (ko) 2002-12-27 2005-07-07 네오바이오다임 주식회사 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 면역크로마토그래피 스트립 및 이 스트립를 이용한 아사이알로 α1-산 당단백질 측정방법
US20040223970A1 (en) 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
NZ577166A (en) 2003-03-04 2010-10-29 Alexion Pharma Inc Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
AU2004223837C1 (en) 2003-03-24 2012-03-15 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
JP2007527712A (ja) 2004-02-12 2007-10-04 レキシコン・ジェネティクス・インコーポレーテッド 新規な遺伝子破壊、これに関する組成物と方法
KR100624013B1 (ko) 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
CA2572133A1 (en) 2004-06-25 2006-01-12 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
EP1671642A1 (en) 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
MX2007007935A (es) 2004-12-28 2007-12-06 Innate Pharma Sa Anticuerpos monoclonales contra nkg2a.
AU2006207945B2 (en) 2005-01-28 2012-02-09 Zymogenetics, Inc. Homogeneous preparations of IL-31
EP1856150A2 (en) 2005-02-14 2007-11-21 ZymoGenetics, Inc. Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
CA2594490A1 (en) 2005-02-14 2006-08-24 Zymogenetics Inc. Methods of treating skin disorders using an il-31ra antagonist
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
RU2444528C2 (ru) 2005-05-06 2012-03-10 Займоджинетикс, Инк. Моноклональные антитела против il-31 и способы применения
KR101446989B1 (ko) * 2005-05-06 2014-10-15 지모제넥틱스, 인코포레이티드 Ｉｌ-31 단클론성 항체 및 사용법
CA2636288C (en) 2006-01-10 2015-02-24 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
ES2586825T3 (es) 2006-01-12 2016-10-19 Alexion Pharmaceuticals, Inc. Anticuerpos para OX-2/CD200 y usos de los mismos
PL2004688T5 (pl) 2006-03-23 2014-09-30 Bioarctic Neuroscience Ab Ulepszone przeciwciała wobec protofibryli oraz ich zastosowania
CL2007001665A1 (es) 2006-06-08 2008-01-18 Chugai Pharmaceutical Co Ltd Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
US7858756B2 (en) 2006-06-15 2010-12-28 The Board Of Trustees Of The University Of Arkansas Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
RU2009111884A (ru) 2006-09-01 2010-10-10 Займоджинетикс, Инк. (Us) Последовательности вариабельных областей моноклональных антител против il-31 и способы использования
BRPI0720280A2 (pt) 2006-12-11 2014-01-28 Wyeth Corp Métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13
CN101600456A (zh) * 2006-12-11 2009-12-09 惠氏公司 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物
DE602008004296D1 (de) 2007-02-14 2011-02-17 Vaccinex Inc Humanisierte anti-cd100-antikörper
PL2059534T3 (pl) 2007-02-23 2012-09-28 Merck Sharp & Dohme Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej
EP2138576A4 (en) 2007-03-16 2011-02-23 Kyowa Hakko Kirin Co Ltd ANTI-CLAUDIN-4 ANTIBODY
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
CA2693611A1 (en) 2007-07-10 2009-01-15 F. Hoffmann-La Roche Ag Novel formulation
DK3059246T3 (en) 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modified constant region of an antibody
WO2009041621A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗il-6レセプター抗体
MX336725B (es) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
BRPI0821110B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
MY185647A (en) 2007-12-05 2021-05-27 Chugai Pharmaceutical Co Ltd Therapeutic agent for pruritus
LT2796466T (lt) 2007-12-07 2018-02-26 Zymogenetics, Inc. Humanizuotų antikūnų molekulės, specifinės il-31 atžvilgiu
KR20160062207A (ko) 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
ES2758827T3 (es) 2009-06-17 2020-05-06 Biomarin Pharm Inc Formulaciones para enzimas lisosómicas
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
HRP20181227T1 (hr) 2012-09-07 2018-10-05 Regeneron Pharmaceuticals, Inc. Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r
EP2970508A4 (en) 2013-03-15 2016-12-14 Permeon Biologics Inc GENETICALLY MODIFIED LOADING ANTIBODIES OR ENHANCED ENHANCEMENT ENHANCEMENT TARGETING PROTEIN COMPOSITIONS AND METHODS OF USE
US9198898B2 (en) * 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
TW201537175A (zh) 2013-06-28 2015-10-01 Chugai Pharmaceutical Co Ltd 預測罹患具皮膚搔癢之疾病的患者對ｉｌ－３１拮抗劑之治療的反應之方法
MA43918A (fr) * 2015-04-14 2018-12-05 Chugai Pharmaceutical Co Ltd Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
GB201703063D0 (en) 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
WO2018156367A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
US10554227B2 (en) * 2017-03-10 2020-02-04 Western Digital Technologies, Inc. Decoding optimization for channel mismatch
US10493149B2 (en) 2017-04-11 2019-12-03 Kiniksa Pharmaceuticals, Ltd. Stable anti-OSMR antibody formulation
CN112512480B (zh) 2018-05-21 2024-10-01 中外制药株式会社 被封入玻璃容器的冷冻干燥制剂
EP4062933A4 (en) 2019-11-20 2023-12-13 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
IL300694A (en) 2020-09-01 2023-04-01 Chugai Pharmaceutical Co Ltd A pharmaceutical preparation for the prevention and/or treatment of dialysis pruritus that includes an IL-31 antagonist as an active ingredient
WO2022113316A1 (ja) 2020-11-30 2022-06-02 マルホ株式会社 線維化の進行抑制剤
KR102902883B1 (ko) 2021-12-22 2025-12-22 추가이 세이야쿠 가부시키가이샤 생물 활성이 저하된 항체 배리언트

Also Published As

Publication number Publication date
KR102514173B1 (ko) 2023-03-27
TW202515609A (zh) 2025-04-16
AU2016248786A1 (en) 2017-10-26
JP2023134842A (ja) 2023-09-27
RU2749512C2 (ru) 2021-06-11
AU2022201346B2 (en) 2024-11-21
TWI738648B (zh) 2021-09-11
BR112017022101A2 (pt) 2018-07-31
KR20210145295A (ko) 2021-12-01
CN107614016A (zh) 2018-01-19
TW201642905A (zh) 2016-12-16
CN107614016B (zh) 2022-06-17
TWI826814B (zh) 2023-12-21
TW202146048A (zh) 2021-12-16
WO2016167263A1 (ja) 2016-10-20
NO2025047I1 (no) 2025-10-23
KR102886159B1 (ko) 2025-11-13
FIC20250033I1 (fi) 2025-10-22
JP2021105051A (ja) 2021-07-26
RU2017138551A3 (enExample) 2019-09-30
US20240018249A1 (en) 2024-01-18
EP4650370A3 (en) 2026-03-11
HUE072989T2 (hu) 2025-12-28
FI3284480T3 (fi) 2025-09-11
JP2021193124A (ja) 2021-12-23
JP6887212B2 (ja) 2021-06-16
CN114848823A (zh) 2022-08-05
LTPA2025537I1 (enExample) 2025-11-10
NL301347I2 (nl) 2025-11-05
KR102641898B1 (ko) 2024-02-27
LT3284480T (lt) 2025-08-11
JP6654967B2 (ja) 2020-02-26
SI3284480T1 (sl) 2025-09-30
CA2980992C (en) 2024-01-23
JP2025122131A (ja) 2025-08-20
KR20230043246A (ko) 2023-03-30
KR20240033097A (ko) 2024-03-12
US20180079817A1 (en) 2018-03-22
RU2017138551A (ru) 2019-05-14
US12441804B2 (en) 2025-10-14
PL3284480T3 (pl) 2025-11-12
CA2980992A1 (en) 2016-10-20
DK3284480T3 (da) 2025-09-08
KR20170134748A (ko) 2017-12-06
MX390570B (es) 2025-03-20
EP3284480B1 (en) 2025-07-02
AU2022201346A1 (en) 2022-03-24
PT3284480T (pt) 2025-07-29
AU2016248786B2 (en) 2022-01-20
EP3284480A4 (en) 2018-12-05
ES3036076T3 (en) 2025-09-12
FR25C1042I1 (fr) 2025-12-19
JPWO2016167263A1 (ja) 2017-06-01
JP2020075937A (ja) 2020-05-21
MX2021013139A (es) 2021-11-25
EP4650370A2 (en) 2025-11-19
TW202327654A (zh) 2023-07-16
JP5954916B1 (ja) 2016-07-20
US20200102396A1 (en) 2020-04-02
HRP20250972T1 (hr) 2025-10-10
EP3284480A1 (en) 2018-02-21
US10544227B2 (en) 2020-01-28
HUS2500042I1 (hu) 2025-11-28
MX2017013141A (es) 2018-02-21
JP2017160178A (ja) 2017-09-14
US11773173B2 (en) 2023-10-03

Similar Documents

Publication Publication Date Title
FR25C1042I1 (fr) Composition pharmaceutique pour la prévention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
EP2818482A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
EP2824114A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
MA43709A (fr) Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations
EP2832366A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF GAD BUBBLE
EP2532743A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
EP2532364A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
EP2832365A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF LIVER CANCER
BR112015026307A2 (pt) heterociclo bicíclicos como inibidores de fgfr
EP3375448A4 (en) STRAIN WITH ABILITY TO INHIBIT FATIBILITY AND PHARMACEUTICAL COMPOSITION THEREOF
FR3032353B1 (fr) Composition pharmaceutique et dispositif pour le traitement de la douleur
EA201692008A1 (ru) Замещенные сконденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EP3539951A4 (en) NEW PYRIMIDINE COMPOUND, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION THEREFORE AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES
EP3403658C0 (en) COMPOSITION FOR THE TREATMENT OF NEUROINFLAMMATORY DISEASES USING NEURAL PRECURSOR CELLS OR SECRETOME THEREOF AS THE ACTIVE INGREDIENT
EP3391904A4 (en) PHARMACEUTICAL COMPOSITION WITH ANTIBODY TO THE HUMAN TSLP RECEPTOR
EP3489252A4 (en) PEPTIDE WITH ANTI-CANCER EFFECT AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER, FUNCTIONAL FOOD COMPOSITION AND FUNCTIONAL COSMETIC COMPOSITION THEREFORE AS AN ACTIVE SUBSTANCE
EP3417853A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER WITH A POLYPHENOL COMPOUND AS A ACTIVE SUBSTANCE
BR112015026685A2 (pt) agente de diminuição de ácido úrico
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
EP3675874A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF KELOID AND USES THEREOF
EP3517133A4 (en) PHARMACEUTICAL COMPOSITION WITH MTOR INHIBITOR FOR TREATING MACRO DEGENERATIONS
HK1257296A1 (zh) 新的化合物及其用途
EP2857037A4 (en) MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERIPHERAL NEUROPATHIC PAIN BY ANTICROBIAL AGENTS
EP3336100A4 (en) PEPTIDE WITH EFFECT FOR PREVENTING OR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM THEREFOR AS AN ACTIVE SUBSTANCE